DK162105C - Sporstofmaerkede konjugater af metallothionein eller et fragment deraf og et antistof eller et fragment deraf, fremgangsmaader til deres fremstilling og mellemprodukt til deres fremstilling - Google Patents

Sporstofmaerkede konjugater af metallothionein eller et fragment deraf og et antistof eller et fragment deraf, fremgangsmaader til deres fremstilling og mellemprodukt til deres fremstilling

Info

Publication number
DK162105C
DK162105C DK480284A DK480284A DK162105C DK 162105 C DK162105 C DK 162105C DK 480284 A DK480284 A DK 480284A DK 480284 A DK480284 A DK 480284A DK 162105 C DK162105 C DK 162105C
Authority
DK
Denmark
Prior art keywords
fragment
metallothionein
conjugates
truck
antibody
Prior art date
Application number
DK480284A
Other languages
English (en)
Other versions
DK480284D0 (da
DK162105B (da
DK480284A (da
Inventor
Glen Lewis Tolman
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of DK480284D0 publication Critical patent/DK480284D0/da
Publication of DK480284A publication Critical patent/DK480284A/da
Publication of DK162105B publication Critical patent/DK162105B/da
Application granted granted Critical
Publication of DK162105C publication Critical patent/DK162105C/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887Antibody-chelate conjugates using chelates for therapeutic purposes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/804Radioisotope, e.g. radioimmunoassay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK480284A 1983-10-06 1984-10-05 Sporstofmaerkede konjugater af metallothionein eller et fragment deraf og et antistof eller et fragment deraf, fremgangsmaader til deres fremstilling og mellemprodukt til deres fremstilling DK162105C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53973383 1983-10-06
US06/539,733 US4732864A (en) 1983-10-06 1983-10-06 Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules

Publications (4)

Publication Number Publication Date
DK480284D0 DK480284D0 (da) 1984-10-05
DK480284A DK480284A (da) 1985-04-07
DK162105B DK162105B (da) 1991-09-16
DK162105C true DK162105C (da) 1992-02-17

Family

ID=24152436

Family Applications (1)

Application Number Title Priority Date Filing Date
DK480284A DK162105C (da) 1983-10-06 1984-10-05 Sporstofmaerkede konjugater af metallothionein eller et fragment deraf og et antistof eller et fragment deraf, fremgangsmaader til deres fremstilling og mellemprodukt til deres fremstilling

Country Status (17)

Country Link
US (1) US4732864A (da)
EP (1) EP0137457B1 (da)
JP (2) JPS60166625A (da)
KR (1) KR860001151B1 (da)
AT (1) ATE32730T1 (da)
AU (1) AU578428B2 (da)
CA (1) CA1248090A (da)
DE (1) DE3469536D1 (da)
DK (1) DK162105C (da)
ES (1) ES8605105A1 (da)
FI (1) FI81263C (da)
GR (1) GR80560B (da)
IE (1) IE55709B1 (da)
IL (1) IL73183A (da)
NO (1) NO166267C (da)
NZ (1) NZ209788A (da)
ZA (1) ZA847797B (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
NO167124C (no) * 1985-04-03 1991-10-09 Du Pont Merck Pharma Fremgangsmaate for fremstilling av et spormerket konjugat av metallthionein og biologisk aktivt molekyl.
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JP2515357B2 (ja) * 1986-01-16 1996-07-10 ザ・ジェネラル・ホスピタル・コ−ポレ−ション 炎症の診断方法および治療方法
US6165729A (en) * 1986-04-30 2000-12-26 Hyperion Catalysis International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US6451225B1 (en) 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5591581A (en) * 1986-04-30 1997-01-07 Igen, Inc. Electrochemiluminescent rhenium moieties and methods for their use
US4877599A (en) * 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
EP0339086B1 (en) * 1987-11-04 1996-09-11 Igen, Inc. Electrochemiluminescent rhenium moieties and methods
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
USH735H (en) 1988-03-30 1990-02-06 The United States Of America As Represented By The United States Department Of Energy Lead-203 as a label for radioimaging
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US6702986B1 (en) 1988-04-29 2004-03-09 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5726153A (en) * 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5218128A (en) * 1988-06-15 1993-06-08 Centocor, Inc. Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
WO1990006323A2 (en) * 1988-11-29 1990-06-14 Centocor, Inc. Chimeric proteins incorporating a metal binding protein
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
US5759515A (en) * 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
US5078985A (en) * 1989-08-09 1992-01-07 Rhomed, Incorporated Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
ES2125854T3 (es) * 1989-08-09 1999-03-16 Rhomed Inc Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio.
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
ATE212059T1 (de) * 1990-02-15 2002-02-15 Methoden zur identifizierung heterofunktionaler fusionsproteine
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
US7238340B1 (en) 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
WO1992013572A1 (en) * 1991-02-08 1992-08-20 Diatech, Inc. TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
US6391590B1 (en) * 1991-10-21 2002-05-21 The Regents Of The University Of California Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
US5738838A (en) * 1992-02-20 1998-04-14 Rhomed Incorporated IKVAV peptide radiopharmaceutical applications
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5643549A (en) * 1992-02-20 1997-07-01 Rhomed Incorporated Leukostimulatory agent for in vivo leukocyte tagging
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5338686A (en) * 1992-04-29 1994-08-16 Hellerstein Marc K Method for measuring in vivo synthesis of biopolymers
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
US6203775B1 (en) * 1993-03-19 2001-03-20 The General Hospital Corporation Chelating polymers for labeling of proteins
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
CA2163107C (en) * 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
DK0710228T3 (da) * 1993-07-19 1998-09-21 Resolution Pharm Inc Hydraziner med N3S-konfiguration som radionuclidchelatorer
WO1995004753A1 (en) * 1993-08-11 1995-02-16 University Of New Mexico Compositions of fusion proteins containing metallothionein and targeting-protein structural components
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6331285B1 (en) 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
EP1100473A2 (en) 1998-07-28 2001-05-23 InnerDyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1121425B1 (en) * 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
WO2000038654A1 (en) * 1998-12-23 2000-07-06 Vallee Bert L Synthetic and therapeutic methods for the alpha and beta domains of metallothionein
AU771248B2 (en) * 1999-01-22 2004-03-18 Martek Biosciences Corporation Simple method for labeled conjugate production
ES2198171B1 (es) * 2000-09-06 2005-04-16 Provital, S.A. Composicion cosmetica y/o farmaceutica conteniendo metalotioneina.
US7385025B2 (en) 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
US20020117169A1 (en) 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
CA2449941A1 (en) * 2001-06-11 2002-12-19 University Of Miami Use of radiopharmaceutical complexes in achieving transplantation tolerance
WO2003101495A1 (en) * 2002-05-29 2003-12-11 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
ATE394675T1 (de) * 2002-10-11 2008-05-15 Sentina Biotechnology Inc Verfahren zum nachweis von brustkrebs
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5-1的特异性抗体及其应用
US7611693B2 (en) 2003-09-17 2009-11-03 Board Of Regents, The Univerisity Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
EP2251695B1 (en) 2003-12-23 2013-07-17 Mount Sinai Hospital Corporation Markers associated with endometrial disease
CN1946741B (zh) * 2004-03-31 2012-09-05 佳能株式会社 金结合蛋白及其用途
WO2006118615A2 (en) * 2004-12-16 2006-11-09 Brandeis University Clonable tag for purification and electron microscopy labeling
US8357720B2 (en) * 2005-03-23 2013-01-22 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
US8765808B2 (en) * 2005-03-23 2014-07-01 Chs Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
EP1865972B1 (en) * 2005-03-23 2013-11-06 CHS Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
US20090312238A1 (en) * 2006-05-03 2009-12-17 Florida Atlantic University Protection Against Oxidative Damage in Cells
GB0621894D0 (en) * 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
US20080269065A1 (en) * 2007-04-30 2008-10-30 Syntrix Biosystems, Inc. Conformationally Constrained Analytical Probes
WO2008141318A1 (en) * 2007-05-14 2008-11-20 Dr. Susan Love Research Foundation Device for determining risk of developing breast cancer and method thereof
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
GB0808086D0 (en) * 2008-05-02 2008-06-11 Iti Scotland Ltd Magnetic proteins for in vivo imaging
EP2300032A4 (en) * 2008-05-13 2012-12-05 Univ Kansas MARKER PRESENTING IN THE FORM OF A MAP PEPTIDE (METAL ABSTRACTION PEPTIDE) AND ASSOCIATED METHODS
CA2768658C (en) 2009-07-22 2018-04-03 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US9040464B2 (en) 2010-08-16 2015-05-26 Mount Sinai Hosptial Markers of the male urogenital tract
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
EP3409297A1 (en) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56125317A (en) * 1980-03-08 1981-10-01 Nippon Mejifuijitsukusu Kk Stable radioactive diagnosticum with radioactive metallic mark
DE3239410A1 (de) * 1981-10-27 1983-05-19 Hybritech Inc., 92121 San Diego, Calif. Monoklonale antikoerper zu tumorassoziiertem antigen, zusammensetzungen, welche diese enthalten und deren anwendung zum tumornachweis
CA1222691A (en) * 1981-12-29 1987-06-09 Wilhelmus T. Goedemans Method of preparing radionuclide-labelled proteins, in particular antibodies or antibody fragments
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies

Also Published As

Publication number Publication date
DK480284D0 (da) 1984-10-05
FI81263B (fi) 1990-06-29
JPH01294700A (ja) 1989-11-28
EP0137457B1 (en) 1988-03-02
NO844017L (no) 1985-04-09
FI843930L (fi) 1985-04-07
KR850002961A (ko) 1985-05-28
NZ209788A (en) 1988-10-28
IL73183A (en) 1991-09-16
AU3362984A (en) 1985-04-18
NO166267C (no) 1991-06-26
GR80560B (en) 1985-02-06
IE842539L (en) 1985-04-06
DK162105B (da) 1991-09-16
FI81263C (fi) 1990-10-10
JPS60166625A (ja) 1985-08-29
EP0137457A2 (en) 1985-04-17
FI843930A0 (fi) 1984-10-05
CA1248090A (en) 1989-01-03
NO166267B (no) 1991-03-18
ES8605105A1 (es) 1986-02-16
JPH0470320B2 (da) 1992-11-10
DK480284A (da) 1985-04-07
ZA847797B (en) 1986-05-28
DE3469536D1 (en) 1988-04-07
EP0137457A3 (en) 1985-08-14
IL73183A0 (en) 1985-01-31
AU578428B2 (en) 1988-10-27
ES536547A0 (es) 1986-02-16
ATE32730T1 (de) 1988-03-15
US4732864A (en) 1988-03-22
KR860001151B1 (ko) 1986-08-18
IE55709B1 (en) 1990-12-19

Similar Documents

Publication Publication Date Title
DK162105C (da) Sporstofmaerkede konjugater af metallothionein eller et fragment deraf og et antistof eller et fragment deraf, fremgangsmaader til deres fremstilling og mellemprodukt til deres fremstilling
OA07695A (fr) Nouvelles hydroxy-3 flavones, leur préparation et leur application thérapeutique.
DK442688D0 (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
NO882385D0 (no) Polypeptid og produksjon derav.
DK235687A (da) Tilberedninger til syntese af prostaglandiner og hydroxyfedtsyrer i biologiske systemer og anvendelse deraf
DE3574875D1 (de) Linsenzusammensetzung, gegenstand und herstellungsverfahren.
DE68919172D1 (de) MOSFET und dessen Herstellungsverfahren.
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
ATE11547T1 (de) Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
DE3850309D1 (de) Hochfrequenz-Bipolartransistor und dessen Herstellungsverfahren.
DE3851815D1 (de) Feldeffekttransistor und dessen Herstellungsmethode.
IS3631A7 (is) Interferons úr hvítum blóðkornum með auknum stöðugleika og aðferð til framleiðslu þeirra
NO880592L (no) Herdbare harpikser, fremgangsmaate for fremstilling av disse og anvendelse av disse.
DK27286A (da) 17a beta-hydroxy-7alfa-methyl-d-homo-19-norandrost-4,16-dien-3-on og 17-estrene deraf, fremstillingsmaader og anvendelser
SE8802040D0 (sv) New use
FR2648923B1 (fr) Procede de fabrication de montres-bracelets et montres-bracelets ainsi realisees
DK0470144T3 (da) D-Asparaginsyre-beta-hydroxamat til behandling af virale infektioner og tumorer
ATE100312T1 (de) Einkristalle von -g(b)-phenylpropiophenonen.
ES1010731U (es) Pieza para ensamblar barras de material didactico en forma ortogonal.
ATE28795T1 (de) Gelatinbasierter vollstaendiger blutersatz und dessen herstellungsverfahren.
IT9017943A0 (it) Agglomerato in miscela particolare composta da cristalli cemento fibreinerti vari in produzione di semilavorato.
NO885058D0 (no) 6-oxoprostaglandin-e-derivater, fremgangsmÿter for fremstilling av disse og deres farmastiske anvendelse.
DK564883A (da) Antistoffer med dobbelt specificitet, og fremstilling og anvendelser deraf
ATE99332T1 (de) Monoklonale antikoerper gegen menschliche interleukin-4 und die sie erzeugenden hybridomen.
ES1000167U (es) Modulo-mueble

Legal Events

Date Code Title Description
PBP Patent lapsed